Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Aptevo Therapeutics Inc. | apvo-10q_20170930.htm |
| EX-31.1 - EX-31.1 - Aptevo Therapeutics Inc. | apvo-ex311_103.htm |
| EX-2.1 - EX-2.1 - Aptevo Therapeutics Inc. | apvo-ex21_142.htm |
| EX-10.2 - EX-10.2 - Aptevo Therapeutics Inc. | apvo-ex102_143.htm |
| EX-31.2 - EX-31.2 - Aptevo Therapeutics Inc. | apvo-ex312_102.htm |
| EX-32.1 - EX-32.1 - Aptevo Therapeutics Inc. | apvo-ex321_101.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aptevo Therapeutics Inc. on Form 10-Q for the period ending September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: November 9, 2017 |
|
By: |
/s/ Jeff Lamothe |
|
|
|
|
Jeff Lamothe |
|
|
|
|
Senior Vice President, Chief Financial Officer, |